Beyond Air Terminates Transaction with XTL Biopharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy XAIR?
Beyond Air (XAIR) announced that the previously disclosed proposed transaction with XTL Biopharmaceuticals (XTLB) relating to Beyond Air's NeuroNOS subsidiary has been terminated. The companies entered into a letter of intent in January 2026 regarding a potential transaction in which XTL would acquire Beyond Air's majority ownership interest in NeuroNOS Ltd. The letter of intent expired on March 9, 2026, in accordance with its terms, and the parties did not enter into a definitive agreement. "While the proposed transaction will not proceed, Beyond Air remains committed to maximizing the value of the NeuroNOS platform," said Steve Lisi, CEO. "We continue to believe NeuroNOS represents a compelling opportunity based on its proprietary small-molecule platform and development programs targeting neurological disorders and oncology." Beyond Air will continue to evaluate strategic alternatives for NeuroNOS and remains focused on advancing its core nitric oxide platform and LungFit programs
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XAIR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XAIR
Wall Street analysts forecast XAIR stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.825
Low
6.00
Averages
6.00
High
6.00
Current: 0.825
Low
6.00
Averages
6.00
High
6.00
About XAIR
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
Beyond Air Terminates Agreement with XTL Biopharmaceuticals
- Agreement Termination: Beyond Air has terminated its agreement with XTL Biopharmaceuticals regarding the sale of its majority stake in NeuroNOS, indicating a significant strategic shift for the company.
- Letter of Intent Expiration: The letter of intent signed in January 2026 expired on March 9, 2026, without a definitive agreement, highlighting potential disagreements on transaction terms between the parties.
- Market Reaction: Beyond Air's stock rose 4.40% in premarket trading to $0.8968, suggesting a degree of market optimism regarding the company's future strategic direction despite the termination.
- Executive Change: The recent appointment of Dan Moorhead as CFO may influence the company's financial management and future investment decisions, potentially impacting shareholder confidence moving forward.
See More
Beyond Air Terminates Proposed Transaction with XTL Biopharmaceuticals
- Transaction Termination: Beyond Air announced the termination of its proposed transaction with XTL Biopharmaceuticals, as the letter of intent signed in January 2026 expired on March 9, 2026, indicating challenges in strategic partnerships for the company.
- NeuroNOS Platform Value: Despite the failed transaction, Beyond Air remains committed to maximizing the value of its NeuroNOS platform, with CEO Steve Lisi emphasizing its potential in treating neurological disorders and oncology, reflecting the company's confidence in future developments.
- Core Technology Advancement: Beyond Air will continue to focus on advancing its core nitric oxide platform and LungFit® programs aimed at improving the quality of life for patients with respiratory illnesses, demonstrating the company's ongoing efforts in medical innovation.
- R&D Prospects: NeuroNOS specializes in developing small-molecule therapies to regulate nitric oxide levels in the brain, with preclinical studies showing potential applications in autism and Alzheimer's disease, highlighting the company's leading position in the neuroscience field.
See More
Potential of High-Dose Inhaled Nitric Oxide for Antimicrobial Therapy
- Publication of Findings: Beyond Air has released an independent review article that comprehensively examines the efficacy of high-dose inhaled nitric oxide (iNO), highlighting its broad-spectrum antimicrobial potential in respiratory infections, which could transform existing treatment paradigms and drive innovation in the medical device sector.
- Compilation of Clinical Evidence: The article synthesizes data from 27 studies, demonstrating the safety and efficacy of high-dose iNO in various respiratory infections, including pneumonia and COVID-19, indicating strategic opportunities for the company in developing new therapies.
- Multimodal Mechanisms: High-dose iNO exhibits multiple mechanisms of action, including direct microbial killing, antiviral effects, and inflammation reduction, emphasizing its potential applications in hospital-acquired pneumonia and immunocompromised patients, potentially filling current treatment gaps.
- Future Research Directions: CEO Steve Lisi stated that the publication will serve as a catalyst for new scientific research, accelerating the clinical development of high-dose iNO and further solidifying the company's leadership position in the treatment of respiratory diseases.
See More
Beyond Air Reports Q3 Earnings with Revenue Beat
- Earnings Report: Beyond Air's Q3 earnings report reveals a GAAP EPS of -$0.85, missing expectations by $0.03, indicating ongoing challenges in profitability.
- Revenue Surge: The company reported revenues of $2.2M for the quarter, representing a substantial year-over-year increase of 105.6%, exceeding market expectations by $0.05M, highlighting strong product demand recovery.
- Executive Appointment: Beyond Air has appointed Dan Moorhead as CFO, aiming to enhance financial management and drive future strategic development for the company.
- Market Reaction: Despite the EPS miss, the significant revenue growth may bolster investor confidence in the company's future growth potential, particularly in the context of new product launches and market expansion efforts.
See More
Beyond Air Reports 105% Revenue Growth in Q3
- Significant Revenue Growth: Beyond Air reported a 105% year-over-year revenue increase to $2.2 million for fiscal Q3 2025, reflecting strong demand for its LungFit PH product in both U.S. and international markets, marking a crucial milestone in the company's commercialization journey.
- Strong Cash Position: As of December 31, 2025, the company reported approximately $22.3 million in cash and cash equivalents, bolstered by recent PIPE financing, which is expected to provide a runway into 2027, enhancing operational sustainability.
- Strategic Acquisition Plan: Beyond Air signed a binding letter of intent to acquire 85% of XTL Biopharmaceuticals, potentially receiving up to $32.5 million in cash and equity, further advancing its strategic positioning in neuro-oncology and autism treatment.
- Clinical Data Presentation: The company plans to present Phase 1a data from its UNO program at the AACR Annual Meeting in 2026, which is expected to increase market awareness of its innovative treatment solutions and support future commercialization efforts.
See More
Life Sciences Virtual Investor Forum Agenda Announced
- Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
- Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
- Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
- Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.
See More
Beyond Air Terminates Agreement with XTL Biopharmaceuticals
- Agreement Termination: Beyond Air has terminated its agreement with XTL Biopharmaceuticals regarding the sale of its majority stake in NeuroNOS, indicating a significant strategic shift for the company.
- Letter of Intent Expiration: The letter of intent signed in January 2026 expired on March 9, 2026, without a definitive agreement, highlighting potential disagreements on transaction terms between the parties.
- Market Reaction: Beyond Air's stock rose 4.40% in premarket trading to $0.8968, suggesting a degree of market optimism regarding the company's future strategic direction despite the termination.
- Executive Change: The recent appointment of Dan Moorhead as CFO may influence the company's financial management and future investment decisions, potentially impacting shareholder confidence moving forward.
See More
Beyond Air Terminates Proposed Transaction with XTL Biopharmaceuticals
- Transaction Termination: Beyond Air announced the termination of its proposed transaction with XTL Biopharmaceuticals, as the letter of intent signed in January 2026 expired on March 9, 2026, indicating challenges in strategic partnerships for the company.
- NeuroNOS Platform Value: Despite the failed transaction, Beyond Air remains committed to maximizing the value of its NeuroNOS platform, with CEO Steve Lisi emphasizing its potential in treating neurological disorders and oncology, reflecting the company's confidence in future developments.
- Core Technology Advancement: Beyond Air will continue to focus on advancing its core nitric oxide platform and LungFit® programs aimed at improving the quality of life for patients with respiratory illnesses, demonstrating the company's ongoing efforts in medical innovation.
- R&D Prospects: NeuroNOS specializes in developing small-molecule therapies to regulate nitric oxide levels in the brain, with preclinical studies showing potential applications in autism and Alzheimer's disease, highlighting the company's leading position in the neuroscience field.
See More
Potential of High-Dose Inhaled Nitric Oxide for Antimicrobial Therapy
- Publication of Findings: Beyond Air has released an independent review article that comprehensively examines the efficacy of high-dose inhaled nitric oxide (iNO), highlighting its broad-spectrum antimicrobial potential in respiratory infections, which could transform existing treatment paradigms and drive innovation in the medical device sector.
- Compilation of Clinical Evidence: The article synthesizes data from 27 studies, demonstrating the safety and efficacy of high-dose iNO in various respiratory infections, including pneumonia and COVID-19, indicating strategic opportunities for the company in developing new therapies.
- Multimodal Mechanisms: High-dose iNO exhibits multiple mechanisms of action, including direct microbial killing, antiviral effects, and inflammation reduction, emphasizing its potential applications in hospital-acquired pneumonia and immunocompromised patients, potentially filling current treatment gaps.
- Future Research Directions: CEO Steve Lisi stated that the publication will serve as a catalyst for new scientific research, accelerating the clinical development of high-dose iNO and further solidifying the company's leadership position in the treatment of respiratory diseases.
See More
Beyond Air Reports Q3 Earnings with Revenue Beat
- Earnings Report: Beyond Air's Q3 earnings report reveals a GAAP EPS of -$0.85, missing expectations by $0.03, indicating ongoing challenges in profitability.
- Revenue Surge: The company reported revenues of $2.2M for the quarter, representing a substantial year-over-year increase of 105.6%, exceeding market expectations by $0.05M, highlighting strong product demand recovery.
- Executive Appointment: Beyond Air has appointed Dan Moorhead as CFO, aiming to enhance financial management and drive future strategic development for the company.
- Market Reaction: Despite the EPS miss, the significant revenue growth may bolster investor confidence in the company's future growth potential, particularly in the context of new product launches and market expansion efforts.
See More
Beyond Air Reports 105% Revenue Growth in Q3
- Significant Revenue Growth: Beyond Air reported a 105% year-over-year revenue increase to $2.2 million for fiscal Q3 2025, reflecting strong demand for its LungFit PH product in both U.S. and international markets, marking a crucial milestone in the company's commercialization journey.
- Strong Cash Position: As of December 31, 2025, the company reported approximately $22.3 million in cash and cash equivalents, bolstered by recent PIPE financing, which is expected to provide a runway into 2027, enhancing operational sustainability.
- Strategic Acquisition Plan: Beyond Air signed a binding letter of intent to acquire 85% of XTL Biopharmaceuticals, potentially receiving up to $32.5 million in cash and equity, further advancing its strategic positioning in neuro-oncology and autism treatment.
- Clinical Data Presentation: The company plans to present Phase 1a data from its UNO program at the AACR Annual Meeting in 2026, which is expected to increase market awareness of its innovative treatment solutions and support future commercialization efforts.
See More
